


Combined targeting of distinct  
c-Myc and JunB transcriptional  
programs induces synergistic  
anti-myeloma activity



**Judith Lind, PhD**  
Karl Landsteiner University of  
Health Sciences, Krems a. d. Donau

Friday, September 10, 2021

# Disclosures

## 1. Employment or Leadership Position

-None

## 2. Advisory Role or Expert Testimony

-None

## 3. Stock Ownership

-None

## 4. Patent, Copyright, Licensing

-None

## 5. Honoraria or Consultancy

-None

## 6. Financing of Scientific Research

Sanofi-Aventis GmbH (travel support)


## 7. Other Financial Relationships

-None


## 8. Immaterial Conflicts of Interest

-None



# Transcription Factors in MM











## Transcription Factors in MM



- Shaulian E, Karin M. NCB. May 2002; 4:131–136.
- Eferl R, Wagner EF. Nat Rev Cancer. 2003; 3(11): 859-68
- Hideshima T, et al. Nat Rev Cancer. 2007; 7: 585-98
- Podar K, Chauhan D, Anderson KC. Leukemia. 2009; 23:10–24
- Fan F, et al. Leukemia. 2016; 6:1-12
- Atsaves V, et al. Cancers 2019, 11, 1037
- Li S, et al. Expert Opin Investig Drugs. 2019 May;28(5):445-462.
- Fan F, et al, Leukemia. 2021 May 18.
- Fan F, Podar K, B, Cancers (Basel). 2021 May 12;13(10):2326.


**Q1: Anti-MM effects of c-Myc inhibition?****Q2: Anti-MM effects of c-Myc inhibition on JunB?****Q3: Anti-MM effects of JunB inhibition on c-Myc?****Q4: Anti-MM effects of combined inhibition of c-Myc and JunB?**

## Importance of Transcription Factors in MM




## Independent expression of c-Myc and JunB


A



B






## No impact of c-Myc inhibition on JunB levels by MZ-1












## Knockdown of JunB has no effect on c-Myc levels

**A****B****C**


## Anti-MM effects of combined c-Myc/JunB inhibition



## No impact on c-Myc levels by MEK-Inhibitor-Trametinib



## A: Anti-MM activity of the PROTAC MZ-1



**Distinct c-Myc and JunB transcriptional programs:  
Rationale for combined targeting of TF in MM**

# Acknowledgements

**Karl Landsteiner University of Health Sciences,  
Krems, Austria**

**Molecular Oncology and Hematology**

- Osman Aksoy
- Vincent Sunder-Plassmann
- Sonia Vallet

Klaus Podar

**Pharmacology**

Dagmar Stoiber-Sakaguchi

**University Hospital, Internal Medicine 2, Krems,  
Austria**

- Elisabeth Zwickl-Traxler
- Martin Pecherstorfer

**Union Hospital, Tongji Medical College,  
Huazhong, University of Science and  
Technology, Institute of Hematology, Wuhan,  
China**

- Fengjuan Fan

**Medical University Vienna Department of  
Medical and Chemical Laboratory Diagnostics/  
Department of Dermatology**

- Latifa Bakiri
- Erwin F. Wagner

**Dana-Farber Cancer Institute, Department of  
Medical Oncology, Boston, United States**

- Martin Sattler

**University of Veterinary Medicine Vienna,  
Austria**

- Karoline Kollmann

